

May 26, 2025

Kidswell Bio Corporation

Chiome Bioscience Inc.

Kidswell Bio and Chiome Bioscience Enter into Master Service Agreement with Mycenax for Development of New Biosimilar Drugs

Kidswell Bio Corporation (“Kidswell”) and Chiome Bioscience Inc. (“Chiome”) are pleased to announce the signing of a Master Service Agreement with Mycenax (“MBI”), a Taiwan-based company with extensive experience in contract development and manufacturing of biopharmaceuticals, including biosimilars. This agreement marks the beginning of a collaborative initiative for the development of new biosimilars.

Following the formation of the strategic alliance in June 2024, Kidswell and Chiome have been jointly advancing joint development of new biosimilars. In May 2025, alongside Alfresa Holdings Corporation, the companies were selected for the Ministry of Health, Labour and Welfare (MHLW)’s subsidy program titled *Subsidy Program for the Development of Domestic Biosimilar Manufacturing Facilities for Biosimilars* (“the Program”). Under the Program, Kidswell and Chiome will leverage their respective CMC capabilities to contribute to the development of new biosimilars.

Under this agreement, Kidswell and Chiome will collaborate with MBI to establish cell lines for new biosimilars. In the future, the companies intend to transfer the manufacturing of biosimilar active pharmaceutical ingredients (“APIs”) – initially produced at MBI’s manufacturing site in Taiwan - to domestic facilities developed under the Program. Through this initiative, they aim to establish a stable domestic supply chain for biosimilars, explore overseas export opportunities for APIs and drug products, and contribute to the advancement of Japan’s biotech industry by nurturing the development of domestic biomanufacturing talent.

About Biosimilar

Biosimilars are pharmaceutical products that offer equivalent quality, safety, and efficacy compared to their reference biologics, while being priced lower under the national drug pricing system. Their broader adoption contributes not only to expanding treatment options for patients, but also to reducing individual healthcare costs and optimizing overall healthcare expenditures. MHLW has been actively promoting the use of biosimilars in recent years.

■ About Mycenax Biotech Inc.

Mycenax Biotech Inc. is a pioneer in the development and manufacturing of biopharmaceuticals in Taiwan. The company provides an integrated value chain encompassing cell line development, process and analytical development, formulation, commercial manufacturing, and aseptic filling. Headquartered in Taiwan, Mycenax offers comprehensive CDMO services to global clients across the biopharmaceutical value chain.

For more information, please visit: <https://mycenax.com/?lang=en>

■ About Alfresa Holdings Corporation

Alfresa Holdings Corporation operates a comprehensive healthcare business that spans pharmaceutical development and manufacturing, distribution, and the operation of dispensing pharmacies. With consolidated net sales exceeding ¥2.9 trillion, the Alfresa Group is Japan's largest pharmaceutical wholesaler in terms of prescription drug distribution.

Guided by its corporate philosophy, "We create and deliver a fresh life for all" the Group plays a critical role in supporting Japan's healthcare infrastructure by maintaining a robust pharmaceutical supply chain and addressing a wide range of medical needs throughout the country.

For more information, please visit: <https://www.alfresa.com/eng/>

■ About Kidswell Bio Corporation

Kidswell Bio Corporation is guided by the mission "Biotech Engineering Company, Striving for Value Creation – For Comprehensive Healthcare System for Children as well as Families and Society". The company has already launched four biosimilar products with partner pharmaceutical companies and established a stable revenue base, while also advancing its cell therapy business, expected to drive future growth. Through its R&D efforts, Kidswell aims to deliver innovative treatments and contribute to a society where patients can live healthier and fulfilled lives.

For more information, please visit: <https://www.kidswellbio.com/en/>

■ About Chiome Bioscience Inc.

Chiome Bioscience Inc. is a biotechnology company dedicated to the discovery and development of antibody therapeutics targeting diseases with high unmet medical needs. Leveraging its proprietary ADLib® system and multi-specific antibody generation technologies such as Tribody®, Chiome actively generates promising antibody drug candidates.

In addition to its Drug Discovery Business, which focuses on in-house antibody drug development, and its Drug Discovery Support Business, which provides high-quality technical services to pharmaceutical companies, Chiome is also promoting collaborations with pharmaceutical companies and startups under an Integrated Drug Discovery (IDD) model, aiming to expand its biosimilar business and contribute to the development of Japan's drug discovery ecosystem.

For more information, please visit: <https://www.chiome.co.jp/?id=en>